Plasma cytokines profile in patients with Alzheimer’s and Parkinson’s Disease: a comparative study in terms of inflammation

References

• Huang M-Y, Tu C-E, Wang S-C, et al. Corylin inhibits LPS-induced inflammatory response and attenuates the activation of NLRP3 inflammasome in microglia. BMC Complement Altern Med. 2018;18(1):221. doi: 10.1186/s12906-018-2287-5.
   PubMed Web of Science ®Google Scholar
• Salcedo I, Tweedie D, Li Y, et al. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol. 2012;166(5):1586–1599. doi: 10.1111/j.1476-5381.2012.01971.x.
   PubMed Web of Science ®Google Scholar
• Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353(6301):777–783. doi: 10.1126/science.aag2590.
   PubMed Web of Science ®Google Scholar
• Van Bulck M, Sierra-Magro A, Alarcon-Gil J, et al. Novel approaches for the treatment of alzheimer’s and parkinson’s disease. Int J Mol Sci. 2019;20(3):719. doi: 10.3390/ijms20030719.
   PubMed Web of Science ®Google Scholar
• Kim DS, Choi H-I, Wang Y, et al. A new treatment strategy for Parkinson’s disease through the gut–brain axis: the glucagon-like peptide-1 receptor pathway. Cell Transplant. 2017;26(9):1560–1571. doi: 10.1177/0963689717721234.
   PubMed Web of Science ®Google Scholar
• Ramesh G, MacLean AG, Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm. 2013;2013:480739. doi: 10.1155/2013/480739.
   PubMed Web of Science ®Google Scholar
• Alam Q, Zubair Alam M, Mushtaq G, et al. Inflammatory process in Alzheimer’s and Parkinson’s diseases: central role of cytokines. Curr Pharm Des. 2016;22(5):541–548. doi: 10.2174/1381612822666151125000300.
   PubMed Web of Science ®Google Scholar
• Delaby C, Gabelle A, Blum D, et al. Central nervous system and peripheral inflammatory processes in Alzheimer’s disease: biomarker profiling approach. Front Neurol. 2015;6:181. doi: 10.3389/fneur.2015.00181.
   PubMed Web of Science ®Google Scholar
• Hong H, Kim BS, Im H-I. Pathophysiological role of neuroinflammation in neurodegenerative diseases and psychiatric disorders. Int Neurourol J. 2016;20(Suppl 1):S2–S7. doi: 10.5213/inj.1632604.302.
   PubMed Web of Science ®Google Scholar
• Reale M, Brenner T, Greig NH, et al. Neuroinflammation, AD, and dementia. Int J Alzheimer’s Dis. 2010;2010:1–2. doi: 10.4061/2010/974026.
   Google Scholar
• Swardfager W, Lanctôt K, Rothenburg L, et al. A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry. 2010;68(10):930–941. doi: 10.1016/j.biopsych.2010.06.012.
   PubMed Web of Science ®Google Scholar
• Lai KSP, Liu CS, Rau A, et al. Peripheral inflammatory markers in Alzheimer’s disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry. 2017;88(10):876–882. doi: 10.1136/jnnp-2017-316201.
   PubMed Web of Science ®Google Scholar
• Martinu K, Nagano-Saito A, Fogel S, et al. Asymmetrical effect of levodopa on the neural activity of motor regions in PD. PLoS One. 2014;9(11):e111600. doi: 10.1371/journal.pone.0111600.
   PubMed Web of Science ®Google Scholar
• Trojanowski JQ, Goedert M, Iwatsubo T, et al. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson’s disease and Lewy body dementia. Cell Death Differ. 1998;5(10):832–837. doi: 10.1038/sj.cdd.4400432.
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Masliah E. Alpha-synuclein in Lewy body disease and Alzheimer’s disease. Brain Pathol. 1999;9(4):707–720. doi: 10.1111/j.1750-3639.1999.tb00552.x.
   PubMed Web of Science ®Google Scholar
• Reale M, Iarlori C, Thomas A, et al. Peripheral cytokines profile in Parkinson’s disease. Brain Behav Immun. 2009;23(1):55–63. doi: 10.1016/j.bbi.2008.07.003.
   PubMed Web of Science ®Google Scholar
• Joshi N, Singh S. Updates on immunity and inflammation in Parkinson disease pathology. J Neurosci Res. 2018;96(3):379–390. doi: 10.1002/jnr.24185.
   PubMed Web of Science ®Google Scholar
• Norden DM, Muccigrosso MM, Godbout JP. Microglial priming and enhanced reactivity to secondary insult in aging, and traumatic CNS injury, and neurodegenerative disease. Neuropharmacology. 2015;96(Pt A):29–41. doi: 10.1016/j.neuropharm.2014.10.028.
   PubMed Web of Science ®Google Scholar
• Cagnin A, Kassiou M, Meikle S, et al. In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurol Scand Suppl. 2006;185(s185):107–114. doi: 10.1111/j.1600-0404.2006.00694.x.
   PubMedGoogle Scholar
• Ferrari CC, Godoy MCP, Tarelli R, et al. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra. Neurobiol Dis. 2006;24(1):183–193. doi: 10.1016/j.nbd.2006.06.013.
   PubMed Web of Science ®Google Scholar
• Liu C, Cui G, Zhu M, et al. Neuroinflammation in Alzheimer’s disease: chemokines produced by astrocytes and chemokine receptors. Int J Clin Exp Pathol. 2014;7(12):8342–8355.
   PubMed Web of Science ®Google Scholar
• Mogi M, Harada M, Riederer P, et al. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165(1–2):208–210. doi: 10.1016/0304-3940(94)90746-3.
   PubMed Web of Science ®Google Scholar
• Lee SC, Zhao M-L, Hirano A, et al. Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J Neuropathol Exp Neurol. 1999;58(11):1163–1169. doi: 10.1097/00005072-199911000-00006.
   PubMed Web of Science ®Google Scholar
• Zhang R, Miller RG, Madison C, et al. Systemic immune system alterations in early stages of alzheimer’s disease. J Neuroimmunol. 2013;256(1–2):38–42. doi: 10.1016/j.jneuroim.2013.01.002.
   PubMed Web of Science ®Google Scholar
• Codolo G, Plotegher N, Pozzobon T, et al. Triggering of inflammasome by aggregated α–synuclein, an inflammatory response in synucleinopathies. PLoS One. 2013;8(1):e55375. doi: 10.1371/journal.pone.0055375.
   PubMed Web of Science ®Google Scholar
• Boka G, Anglade P, Wallach D, et al. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett. 1994;172(1–2):151–154. doi: 10.1016/0304-3940(94)90684-x.
   PubMed Web of Science ®Google Scholar
• Tanioka T, Nakatani Y, Semmyo N, et al. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2biosynthesis. J Biol Chem. 2000;275(42):32775–32782. doi: 10.1074/jbc.M003504200.
   PubMed Web of Science ®Google Scholar
• Jakobsson P-J, Thorén S, Morgenstern R, et al. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A. 1999;96(13):7220–7225. doi: 10.1073/pnas.96.13.7220.
   PubMed Web of Science ®Google Scholar
• Mancini JA, Blood K, Guay J, et al. Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. J Biol Chem. 2001;276(6):4469–4475. doi: 10.1074/jbc.M006865200.
   PubMed Web of Science ®Google Scholar
• Thorén S, Jakobsson PJ. Coordinate up-and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells: inhibition by NS-398 and leukotriene C4. Eur J Biochem. 2000;267(21):6428–6434. doi: 10.1046/j.1432-1327.2000.01735.x.
   PubMedGoogle Scholar
• Williams JA, Shacter E. Regulation of macrophage cytokine production by prostaglandin E2: distinct roles of cyclooxygenase-1 and-2. J Biol Chem. 1997;272(41):25693–25699. doi: 10.1074/jbc.272.41.25693.
   PubMed Web of Science ®Google Scholar
• Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci U S A. 1996;93(10):4885–4890. doi: 10.1073/pnas.93.10.4885.
   PubMed Web of Science ®Google Scholar
• Hoshino T, Namba T, Takehara M, et al. Prostaglandin E2 stimulates the production of amyloid-β peptides through internalization of the EP4 receptor. J Biol Chem. 2009;284(27):18493–18502. doi: 10.1074/jbc.M109.003269.
   PubMed Web of Science ®Google Scholar
• Ravaglia G, Forti P, Maioli F, et al. Plasma homocysteine and inflammation in elderly patients with cardiovascular disease and dementia. Exp Gerontol. 2004;39(3):443–450. doi: 10.1016/j.exger.2003.11.005.
   PubMed Web of Science ®Google Scholar
• Tesco G, Lomoio S. Pathophysiology of neurodegenerative diseases: an interplay among axonal transport failure, oxidative stress, and inflammation? Semin Immunol. 2022;59:101628. doi: 10.1016/j.smim.2022.101628.
   PubMed Web of Science ®Google Scholar
• Tansey MG, Wallings RL, Houser MC, et al. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657–673. doi: 10.1038/s41577-022-00684-6.
   PubMed Web of Science ®Google Scholar
• Reale M, Greig N, Kamal M. Peripheral chemo-cytokine profiles in Alzheimer’s and Parkinson’s diseases. Mini Rev Med Chem. 2009;9(10):1229–1241. doi: 10.2174/138955709789055199.
   PubMed Web of Science ®Google Scholar
• Xie J, Van Hoecke L, Vandenbroucke RE. The impact of systemic inflammation on Alzheimer’s disease pathology. Front Immunol. 2021;12:796867. doi: 10.3389/fimmu.2021.796867.
   PubMed Web of Science ®Google Scholar
• Guerreiro RJ, Santana I, Brás JM, et al. Peripheral inflammatory cytokines as biomarkers in Alzheimer’s disease and mild cognitive impairment. Neurodegener Dis. 2007;4(6):406–412. doi: 10.1159/000107700.
   PubMed Web of Science ®Google Scholar
• Brodacki B, Staszewski J, Toczyłowska B, et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett. 2008;441(2):158–162. doi: 10.1016/j.neulet.2008.06.040.
   PubMed Web of Science ®Google Scholar
• Qin X-Y, Zhang S-P, Cao C, et al. Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol. 2016;73(11):1316–1324. doi: 10.1001/jamaneurol.2016.2742.
   PubMed Web of Science ®Google Scholar
• Zuliani G, Ranzini M, Guerra G, et al. Plasma cytokines profile in older subjects with late onset Alzheimer’s disease or vascular dementia. J Psychiatr Res. 2007;41(8):686–693. doi: 10.1016/j.jpsychires.2006.02.008.
   PubMed Web of Science ®Google Scholar
• Koziorowski D, Tomasiuk R, Szlufik S, et al. Inflammatory cytokines and NT-proCNP in Parkinson’s disease patients. Cytokine. 2012;60(3):762–766. doi: 10.1016/j.cyto.2012.07.030.
   PubMed Web of Science ®Google Scholar
• Song I-U, Kim J-S, Chung S-W, et al. Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson’s disease? A comparison of Parkinson’s disease patients, disease controls and healthy individuals. Eur Neurol. 2009;62(2):99–104. doi: 10.1159/000222780.
   PubMed Web of Science ®Google Scholar
• Corsi MM, Licastro F, Porcellini E, et al. Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease: relationship with neuro-degeneration. Biogerontology. 2011;12(5):451–454. doi: 10.1007/s10522-011-9335-6.
   PubMed Web of Science ®Google Scholar
• Bonotis K, Krikki E, Holeva V, et al. Systemic immune aberrations in Alzheimer’s disease patients. J Neuro­immunol. 2008;193(1–2):183–187. doi: 10.1016/j.jneuroim.2007.10.020.
   PubMed Web of Science ®Google Scholar
• Reale M. Cytokines in chronic neurodegenerative diseases. Alzheimers Park Dis Open Access. 2015;1:4–6.
   Google Scholar
• Tweedie D, Sambamurti K, Greig NH. TNF-α inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res. 2007;4(4):378–385. doi: 10.2174/156720507781788873.
   PubMed Web of Science ®Google Scholar
• Chadwick W, Magnus T, Martin B, et al. Targeting TNF-α receptors for neurotherapeutics. Trends Neurosci. 2008;31(10):504–511. doi: 10.1016/j.tins.2008.07.005.
   PubMed Web of Science ®Google Scholar
• Yan Y, Jiang W, Liu L, et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell. 2015;160(1–2):62–73. doi: 10.1016/j.cell.2014.11.047.
   PubMed Web of Science ®Google Scholar
• Porro C, Cianciulli A, Panaro MA. The regulatory role of IL-10 in neurodegenerative diseases. Biomolecules. 2020;10(7):1017. doi: 10.3390/biom10071017.
   PubMed Web of Science ®Google Scholar
• Gupta V, Garg RK, Khattri S. Levels of IL-8 and TNF-α decrease in Parkinson’s disease. Neurol Res. 2016;38(2):98–102. doi: 10.1080/01616412.2015.1133026.
   PubMed Web of Science ®Google Scholar
• Belkhelfa M, Rafa H, Medjeber O, et al. IFN-γ and TNF-α are involved during Alzheimer disease progression and correlate with nitric oxide production: a study in Algerian patients. J Interferon Cytokine Res. 2014;34(11):839–847. doi: 10.1089/jir.2013.0085.
   PubMed Web of Science ®Google Scholar
• Cojocaru IM, Cojocaru M, Miu G, et al. Study of interleukin-6 production in Alzheimer’s disease. Rom J Intern Med. 2011;49(1):55–58.
   PubMedGoogle Scholar
• Italiani P, Puxeddu I, Napoletano S, et al. Circulating levels of IL-1 family cytokines and receptors in Alzheimer’s disease: new markers of disease progression? J Neuroinflammation. 2018;15(1):342. doi: 10.1186/s12974-018-1376-1.
   PubMed Web of Science ®Google Scholar
• Gezen-Ak D, Dursun E, Hanağası H, et al. BDNF, TNFα, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer’s disease or mild cognitive impairment. J Alzheimers Dis. 2013;37(1):185–195. doi: 10.3233/JAD-130497.
   PubMed Web of Science ®Google Scholar
• Alsadany MA, Shehata HH, Mohamad MI, et al. Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2013;28(1):54–61. doi: 10.1177/1533317512467680.
   PubMed Web of Science ®Google Scholar
• Wojno EDT, Hunter CA, Stumhofer JS. The immunobiology of the interleukin-12 family: room for discovery. Immunity. 2019;50(4):851–870. doi: 10.1016/j.immuni.2019.03.011.
   PubMed Web of Science ®Google Scholar
• Álvarez-Luquín DD, Arce-Sillas A, Leyva-Hernández J, et al. Regulatory impairment in untreated Parkinson’s disease is not restricted to tregs: other regulatory populations are also involved. J Neuroinflammation. 2019;16(1):212. doi: 10.1186/s12974-019-1606-1.
   PubMed Web of Science ®Google Scholar
• Mattammal MB, Strong R, Lakshmi VM, et al. Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson’s disease. J Neurochem. 1995;64(4):1645–1654. doi: 10.1046/j.1471-4159.1995.64041645.x.
   PubMed Web of Science ®Google Scholar
• Rocha NP, Scalzo PL, Barbosa IG, et al. Cognitive status correlates with CXCL10/IP-10 levels in Parkinson’s disease. Parkinson’s Disease. 2014;2014:1–7. doi: 10.1155/2014/903796.
   Web of Science ®Google Scholar
• Galimberti D, Fenoglio C, Lovati C, et al. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease. Neurobiol Aging. 2006;27(12):1763–1768. doi: 10.1016/j.neurobiolaging.2005.10.007.
   PubMed Web of Science ®Google Scholar
• Qin W, Ho L, Pompl PN, et al. Cyclooxygenase (COX)-2 and COX-1 potentiate β-amyloid peptide generation through mechanisms that involve γ-secretase activity. J Biol Chem. 2003;278(51):50970–50977. doi: 10.1074/jbc.M307699200.
   PubMed Web of Science ®Google Scholar
• Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. 2014;40(3):315–327. doi: 10.1016/j.immuni.2014.02.009.
   PubMed Web of Science ®Google Scholar